Literature DB >> 23533183

Type I interferon receptor deficiency prevents murine Sjogren's syndrome.

B M Szczerba1, P D Rybakowska, P Dey, K M Payerhin, A B Peck, H Bagavant, U S Deshmukh.   

Abstract

In Sjögren's Syndrome (SS), inherent glandular defects, autoimmunity, and mononuclear cell infiltration within the salivary glands cause reduced salivation leading to xerostomia. Excessive production of type I interferons (IFN), triggered by environmental and genetic factors, is considered pathogenic in this disorder. However, whether type I IFN production is causative or an outcome of the disease process is not known. To address this question, we introduced a deficiency of interferon alpha receptor 1 (Ifnar1) into B6.Aec1Aec2 mice, which are known to have the genetic loci necessary for developing a SS-like disorder. This new mouse strain, B6.Aec1Aec2Ifnar1 (-/-), lacking type I IFN-mediated signaling, was characterized for pilocarpine-induced salivation, the presence of serum autoantibodies, sialoadenitis, and dacryoadenitis. Compared with the B6.Aec1Aec2Ifnar1 (+/+) (wild-type) mice, the B6.Aec1Aec2Ifnar1 (-/-) (knockout) mice had significantly lower mononuclear cell infiltration in the salivary and lacrimal glands. The knockout mice were completely protected from salivary gland dysfunction. Surprisingly, they had a robust autoantibody response comparable with that of the wild-type mice. These findings demonstrate that, in the absence of type I IFN-mediated signaling, systemic autoantibody responses can be dissociated from glandular pathology. Our study suggests that, in genetically susceptible individuals, the type I IFN pathway can instigate certain features of SS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23533183      PMCID: PMC3627507          DOI: 10.1177/0022034513483315

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  29 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

Authors:  Karl S Lang; Panco Georgiev; Mike Recher; Alexander A Navarini; Andreas Bergthaler; Mathias Heikenwalder; Nicola L Harris; Tobias Junt; Bernhard Odermatt; Pierre-Alain Clavien; Hanspeter Pircher; Shizuo Akira; Hans Hengartner; Rolf M Zinkernagel
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

3.  Sjögren's syndrome-like disease of C57BL/6.NOD-Aec1 Aec2 mice: gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus.

Authors:  C Nguyen; E Singson; J-Y Kim; J G Cornelius; R Attia; M E Doyle; M Bulosan; S Cha; A B Peck
Journal:  Scand J Immunol       Date:  2006-09       Impact factor: 3.487

4.  Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

Authors:  Trond Ove R Hjelmervik; Kjell Petersen; Inge Jonassen; Roland Jonsson; Anne Isine Bolstad
Journal:  Arthritis Rheum       Date:  2005-05

5.  Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease.

Authors:  Harini Bagavant; Claire Thompson; Katsuhiro Ohno; Yulius Setiady; Kenneth S K Tung
Journal:  Int Immunol       Date:  2002-12       Impact factor: 4.823

Review 6.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

7.  Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background.

Authors:  Seunghee Cha; Hiroyuki Nagashima; Vinette B Brown; Ammon B Peck; Michael G Humphreys-Beher
Journal:  Arthritis Rheum       Date:  2002-05

8.  Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production.

Authors:  Kei Yasuda; Christophe Richez; Joseph W Maciaszek; Neerja Agrawal; Shizuo Akira; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

9.  Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function.

Authors:  Umesh S Deshmukh; Seshagiri Rao Nandula; Pushpa-Rekha Thimmalapura; Yogesh M Scindia; Harini Bagavant
Journal:  J Oral Pathol Med       Date:  2009-01       Impact factor: 4.253

10.  Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies.

Authors:  U S Deshmukh; J E Lewis; F Gaskin; C C Kannapell; S T Waters; Y H Lou; K S Tung; S M Fu
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

View more
  23 in total

1.  When killers become helpers.

Authors:  Umesh S Deshmukh; Harini Bagavant
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

2.  Anti-IL-7 receptor-α treatment ameliorates newly established Sjögren's-like exocrinopathy in non-obese diabetic mice.

Authors:  Jing Zhou; Qing Yu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-19       Impact factor: 5.187

3.  Plasmacytoid dendritic cells promote the pathogenesis of Sjögren's syndrome.

Authors:  Jing Zhou; Xiaofeng Zhang; Qing Yu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-11-12       Impact factor: 5.187

4.  Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.

Authors:  Jing Zhou; Bo Ra You; Qing Yu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-11-15       Impact factor: 5.187

Review 5.  Childhood Sjögren syndrome: insights from adults and animal models.

Authors:  Scott M Lieberman
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

6.  Alum, an aluminum-based adjuvant, induces Sjögren's syndrome-like disorder in mice.

Authors:  H Bagavant; S R Nandula; P Kaplonek; P D Rybakowska; U S Deshmukh
Journal:  Clin Exp Rheumatol       Date:  2014-04-09       Impact factor: 4.473

7.  Protocols for Experimental Sjögren's Syndrome.

Authors:  Harini Bagavant; Umesh S Deshmukh
Journal:  Curr Protoc Immunol       Date:  2020-12

8.  Upregulated Chemokine and Rho-GTPase Genes Define Immune Cell Emigration into Salivary Glands of Sjögren's Syndrome-Susceptible C57BL/6.NOD-Aec1Aec2 Mice.

Authors:  Ammon B Peck; Cuong Q Nguyen; Julian L Ambrus
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

Review 9.  The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives.

Authors:  Nicoletta Del Papa; Antonina Minniti; Maurizio Lorini; Vincenzo Carbonelli; Wanda Maglione; Francesca Pignataro; Nicola Montano; Roberto Caporali; Claudio Vitali
Journal:  Biomolecules       Date:  2021-02-09

Review 10.  The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man.

Authors:  Naomi I Maria; Petra Vogelsang; Marjan A Versnel
Journal:  Arthritis Res Ther       Date:  2015-07-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.